FY2017 EPS Estimates for Xencor, Inc. Decreased by Analyst (XNCR)
Xencor, Inc. (NASDAQ:XNCR) – Investment analysts at Wedbush decreased their FY2017 earnings per share (EPS) estimates for shares of Xencor in a report issued on Wednesday. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of ($1.06) for the year, down from their previous forecast of ($1.02). Wedbush also issued estimates for Xencor’s Q4 2017 earnings at ($0.27) EPS, Q1 2018 earnings at ($0.43) EPS, Q2 2018 earnings at ($0.45) EPS, Q3 2018 earnings at ($0.48) EPS, Q4 2018 earnings at ($0.47) EPS, FY2018 earnings at ($1.83) EPS, FY2019 earnings at ($1.91) EPS, FY2020 earnings at ($0.46) EPS and FY2021 earnings at ($1.66) EPS.
TRADEMARK VIOLATION WARNING: “FY2017 EPS Estimates for Xencor, Inc. Decreased by Analyst (XNCR)” was reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/fy2017-eps-estimates-for-xencor-inc-decreased-by-analyst-xncr/1694480.html.
Other equities analysts also recently issued reports about the company. Zacks Investment Research downgraded Xencor from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Canaccord Genuity restated a “buy” rating and issued a $36.00 price target on shares of Xencor in a research note on Tuesday, August 8th. ValuEngine downgraded Xencor from a “hold” rating to a “sell” rating in a research report on Monday, October 23rd. Finally, BidaskClub downgraded Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Three analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. Xencor currently has an average rating of “Hold” and an average price target of $28.67.
Xencor (XNCR) opened at $21.03 on Friday. Xencor has a 52 week low of $18.55 and a 52 week high of $29.38.
A number of large investors have recently bought and sold shares of the business. Virginia Retirement Systems ET AL raised its holdings in Xencor by 10.0% during the third quarter. Virginia Retirement Systems ET AL now owns 76,200 shares of the biopharmaceutical company’s stock valued at $1,747,000 after acquiring an additional 6,900 shares during the period. Great West Life Assurance Co. Can raised its holdings in Xencor by 158.9% during the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 4,005 shares during the period. TD Asset Management Inc. raised its holdings in Xencor by 20.5% during the third quarter. TD Asset Management Inc. now owns 98,521 shares of the biopharmaceutical company’s stock valued at $2,258,000 after acquiring an additional 16,752 shares during the period. Artal Group S.A. bought a new stake in Xencor during the third quarter valued at about $2,292,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in Xencor during the third quarter valued at about $572,000. 76.81% of the stock is currently owned by institutional investors and hedge funds.
In other Xencor news, major shareholder John S. Stafford III purchased 43,500 shares of the firm’s stock in a transaction on Friday, August 18th. The shares were acquired at an average cost of $19.93 per share, with a total value of $866,955.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder John S. Stafford III purchased 25,000 shares of the firm’s stock in a transaction on Wednesday, August 16th. The shares were acquired at an average cost of $20.96 per share, for a total transaction of $524,000.00. The disclosure for this purchase can be found here. Insiders have purchased 427,209 shares of company stock worth $8,537,686 over the last quarter. 4.03% of the stock is owned by company insiders.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.